The emergence of neoadjuvant immune- over BRAF therapy in melanoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39039662.
- Also identified by DOI 10.1002/cncr.35490 and PMC identifier 11436295.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neoadjuvant therapy has emerged in high-risk stage III melanoma with immunotherapy improving long-term outcomes when compared with BRAF and MEK inhibition. Unmet needs remain surrounding optimal immunotherapy combinations, selection biomarkers and deintensification of treatment.
Medical subject headings
- Melanoma
- Proto-Oncogene Proteins B-raf
- Neoadjuvant Therapy